On December 2, 2024, Michael Mcbreen, Executive Vice President & President, Codman Specialty Surgical at Integra Lifesciences Holdings Corp (IART, Financial), sold 1,700 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns 56,182 shares of the company.
Integra Lifesciences Holdings Corp (IART) is a global leader in medical technology, offering innovative solutions in neurosurgery, reconstructive, and general surgery. The company is known for its comprehensive portfolio of products that improve patient outcomes and enhance the quality of life.
The insider transaction history for Integra Lifesciences Holdings Corp shows that there have been two insider buys and three insider sells over the past year. This recent sale by Michael Mcbreen is part of the broader trend of insider activity within the company.
On the day of the sale, shares of Integra Lifesciences Holdings Corp were trading at $24.16, giving the stock a market cap of $1.9 billion. The company's valuation metrics include a price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
The stock's GF Value is estimated at $49.17, resulting in a price-to-GF-Value ratio of 0.49. This suggests that the stock is considered a "Possible Value Trap, Think Twice" based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples, a GuruFocus adjustment factor, and future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
